Preeclampsia diagnostic market projected to reach USD 1.59 billion by 2032.
From GlobeNewswire: 2025-01-07 08:00:00
The Preeclampsia Diagnostics Market was valued at USD 1.22 Billion in 2023, projected to reach USD 1.59 Billion by 2032 with a CAGR of 2.98%. Rising preeclampsia cases and advanced detection technologies are driving market growth, emphasizing early detection to reduce maternal and fetal morbidity.
Blood tests dominate the market with a 60% share due to their precision in detecting key biomarkers. Urine analysis is the fastest-growing segment, offering non-invasive and cost-effective diagnostic methods for early preeclampsia detection, especially in resource-limited settings.
Consumables like reagents and assay kits lead the market at 55% share, essential for diagnostic tests. Automated analyzers and portable devices are the fastest-growing instrument segment, providing rapid and accurate results for point-of-care settings.
North America holds the largest market share in 2023, driven by advanced healthcare infrastructure and maternal health awareness. The Asia Pacific region is expected to grow rapidly, with countries like China and India witnessing advancements in healthcare technologies and increased access to preeclampsia diagnostics.
Gravidas Diagnostics received USD 3 million in December 2024 for developing a home-based fingerstick test for preeclampsia, showcasing ongoing innovations in the field. Trinity Biotech plc acquired Metabolomics Diagnostics for USD 1.3 million in 2024. CSEM and MOMM Diagnostics collaborated in 2023 to develop a point-of-care solution for early preeclampsia diagnosis. The multi-analyte sensor targets associated biomarkers in a single test, revolutionizing diagnostic capabilities. Market analysis and outlook reports are available for purchase for further insights. SNS Insider is a leading market research and consulting agency offering valuable data for informed decision-making.
Read more at GlobeNewswire: Preeclampsia Diagnostics Market Size to Reach USD 1.59